Towards Preclinical Validation of Arbaclofen (R-baclofen) Treatment for 16p11.2 Deletion Syndrome
Brigitta B. Gundersen, William T. O’Brien, Melanie D. Schaffler, Maria N. Schultz, Tatsuya Tsukahara, Sandra Martín Lorenzo, Valérie Nalesso, Alice Luo Clayton, Ted G. Abel, Jacqueline N. Crawley, Sandeep Robert Datta, Yann Hérault
Experiments across four laboratories found that arbaclofen rescued cognitive deficits in mouse models of 16p11.2 deletion, without sedation or significant off-target behavioral effects.
bioRxiv · May 1, 2023 · PreprintNeuroscience